Back

Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks - rebuttal and discussion.

4 April 2022 (10:30 - 10:40)
Organised by:
Congress Presentation Part of: Controversies in ventricular tachycardia (VT) ablation Catheter Ablation of Arrhythmias EHRA Premium Access EHRA 2022

5 More presentations in this session

Presentation thumbnail
What will improve the results of VT ablation? Better mapping.
Doctor P. Maury (Toulouse, FR)
Slides Video
Presentation thumbnail
What will improve the results of VT ablation? Better technology.
Professor J. Kautzner (Prague, CZ)
Slides
Presentation thumbnail
What will improve the results of VT ablation? - rebuttal and discussion.
Presentation thumbnail
Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks: drugs?
Professor A. Goette (Paderborn, DE)
Slides
Presentation thumbnail
Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks: ablation?
Doctor M. Saba (London, GB)
Slides

Access the full session

Session thumbnail
Controversies in ventricular tachycardia (VT) ablation

The Event

Event poster

EHRA 2022

4 April 2022 10:30 CET
You may be interested in
thumbnail
Congress Session
Debate on primary prevention in ICD therapy
30 March 2025
thumbnail
Congress Session
Ventricular storm (3)
31 March 2025
thumbnail
Congress Presentation
Reduction in shock burden with catheter ablation versus escalated antiarrhythmic drug therapy: Insights from the VANISH trial
3 April 2022
thumbnail
Congress Session
Atrioventricular block
1 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources